MeiraGTx

MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients with acquired and inherited diseases. The company is a vertically integrated clinical-stage gene therapy company with five ongoing clinical programs and a wide range of preclinical and research projects. MeiraGTx has core competencies in viral vector design and optimization, gene therapy manufacturing, and potentially transformative gene regulation technologies. Led by an experienced management team, the company adopts a portfolio approach, licensing, acquiring, and developing technologies that provide deep insights into candidate products and indications. While initially focused on the eye, salivary glands, and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapies for patients with a range of serious diseases.